Transcriptional profiles predict treatment outcome in patients with tuberculosis and diabetes at diagnosis and at two weeks after initiation of anti-tuberculosis treatment

Authors

Cassandra L.R. van Doorn^{1,#}, Clare Eckold^{2,#}, Katharina Ronacher^{3,4}, Rovina Ruslami^{5,6}, Suzanne van Veen¹, Ji-Sook Lee², Vinod Kumar^{7,8}, Sarah Kerry-Barnard⁹, Stephanus T. Malherbe³, Léanie Kleynhans³, Kim Stanley³, Philip C. Hill¹⁰, Simone A. Joosten¹, Reinout van Crevel^{8,11}, Cisca Wijmenga⁷, Julia A. Critchley⁹, Gerhard Walzl³, Bakti Alisjahbana^{5,6}, Mariëlle C. Haks¹, Hazel M. Dockrell², Tom H. M. Ottenhoff¹, Eleonora Vianello^{1*} and Jacqueline M. Cliff^{2*}, on behalf of the TANDEM Consortium^{\$}

[#]These authors contributed equally to this work

^{*}These authors contributed equally to this work

Correspondence:

Dr. Eleonora Vianello

Email: e.vianello@lumc.nl

Telephone: +31 71 52 63844

ORCID: 0000-0003-0342-4055

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

¹Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands

²Dept of Infection Biology and TB Centre, London School of Hygiene & Tropical Medicine, London, WC1E 7HT, United Kingdom

³SA MRC Centre for TB Research, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Department of Biomedical Sciences, Stellenbosch University, Cape Town, South Africa

⁴Mater Research Institute – The University of Queensland, Translational Research Institute, Brisbane, QLD, Australia

⁵TB-HIV Research Center, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia

⁶Hasan Sadikin General Hospital, Bandung, Indonesia

⁷University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, the Netherlands

⁸Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands

⁹Population Health Research Institute, St George's Hospital Medical School, University of London.

¹⁰Centre for International Health, Division of Health Sciences, University of Otago, Dunedin, New Zealand

¹¹Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

Abstract

Background

Globally, the anti-tuberculosis (TB) treatment success rate is approximately 85%, with treatment failure, relapse and death occurring in a significant proportion of pulmonary TB patients. Treatment success is lower among people with diabetes mellitus (DM). Predicting treatment failure early after diagnosis would allow early treatment adaptation and may improve global TB control.

Methods

Samples were collected in a longitudinal cohort study of adult TB patients with or without concomitant DM from South Africa and Indonesia to characterize whole blood transcriptional profiles before and during anti-TB treatment, using unbiased RNA-Seq and targeted gene dcRT-MLPA.

Findings

We report differences in whole blood transcriptome profiles, which were observed before initiation of treatment and throughout treatment, between patients with a good versus poor anti-TB treatment outcome. An eight-gene and a 22-gene blood transcriptional signature distinguished patients with a good treatment outcome from patients with a poor treatment outcome at diagnosis (AUC=0.815) or two weeks (AUC=0.834) after initiation of anti-TB treatment, respectively. High accuracy was obtained by cross-validating this signature in an external cohort (AUC=0.749).

Interpretation

These findings suggest that transcriptional profiles can be used as a prognostic biomarker for treatment failure and success, even in patients with concomitant DM.

Funding

The research leading to these results, as part of the TANDEM Consortium, received funding from the European Community's Seventh Framework Programme (FP7/2007-2013 Grant Agreement No. 305279) and the Netherlands Organization for Scientific Research (NWO-TOP Grant Agreement No. 91214038).

Keywords (4-6)

Biomarkers, tuberculosis, treatment outcome, diabetes mellitus

Introduction

With more than 10 million new cases and approximately 1.5 million deaths annually, tuberculosis (TB), which is caused by *Mycobacterium tuberculosis* (*Mtb*), continues to be a major global health threat.¹ Upon infection with *Mtb*, 5-10% of adults develop active disease during their lifetime and one quarter of the world's population is estimated to be latently infected with *Mtb* (LTBI). The global anti-TB treatment success rate is only about 85% and even lower in patients with multi-drug resistant TB or with comorbidities like HIV or diabetes mellitus (DM)¹⁻³, resulting in a significant number of patients with poor clinical outcomes.

DM triples the risk of developing active TB⁴ and increases the risk of poor clearance of the infection following anti-TB treatment.⁵⁻⁷ In 2020, 0.37 million TB cases were estimated to suffer from DM comorbidity.¹ 85-95% of all DM cases is attributed to type-2 diabetes mellitus (T2DM).⁸ Since global DM prevalence is estimated to rise from 463 million people in 2019 to 700 million in 2045⁹, in particular in areas where TB is endemic, there is increasing concern about the consequences of the rising DM prevalence for global TB control.¹ The mechanisms underlying DM-induced treatment failure remain, however, poorly understood.

Prediction of treatment failure based on sputum-smear microscopy and mycobacterial culture lacks sensitivity¹⁰ and depends on the quality of sputum samples, which are difficult to collect and are frequently inconsistent in quality.¹¹⁻¹³ In addition to more advanced sputum-based diagnostics, monitoring of whole blood transcriptomics may be an additional, complementary but independent method to monitor treatment responses, possibly with increased sensitivity.¹⁴ Numerous studies have reported transcriptional biomarker profiles for active TB and response to anti-TB treatment using whole-blood or PBMCs in settings with varying TB incidence.¹⁵⁻²⁰ In addition, multiple studies have demonstrated the predictive potential of host gene biomarkers in identifying patients at risk of developing active TB, relapse and treatment failure.²¹⁻²⁸ Together, these studies showed that gene signatures may have utility

at predicting anti-TB treatment success versus failure already early after TB diagnosis, providing a significant improvement over the currently used low sensitivity conversion to negative sputum-based culture testing.¹⁰ Despite the high incidence of DM and pre-DM among TB patients in TB-endemic settings^{7,29-31}, only a few studies have identified or validated such signatures in TB patients with DM or hyperglycemia.^{32,33}

Characterizing transcriptomic profiles may improve our understanding towards the immunological pathways that are involved in DM-associated TB pathology and monitoring treatment success and failure in TB patients with concomitant DM is key to combat the tuberculosis-diabetes (TB-DM) co-epidemic. Although the blood transcriptome profile of TB-DM patients is more similar to TB patients than to DM patients, suggesting a dominant influence of active TB infection, we and others recently demonstrated significant differences in the blood transcriptome of TB-DM patients compared to TB patients.^{32,33} Additionally, the transcriptomic profiles of patients with TB-related intermediate hyperglycemia (TBrel-IH) were similar to the profiles of TB-DM patients.³² Importantly, we also showed that DM comorbidity lowered the performance of published diagnostic biomarker signatures.³² Therefore, there is a need for biomarkers that predict treatment success and failure in TB patients independently of their glycemia or DM status.

The aim of the current study was to identify blood transcriptional gene signature for predicting the anti-TB treatment outcome at an early stage after initiation of anti-TB treatment, irrespective of concomitant DM. We combined an unbiased RNA-Seq approach and a selective dcRT-MLPA approach (a multiplex RT-PCR platform) as two independent strategies to identify gene signatures with high discriminatory power to distinguish patients with a good treatment outcome from patients with a poor treatment outcome. Host gene biomarker profiles to identify anti-TB treatment success or failure could facilitate the evaluation of new anti-TB

drugs and improve clinical surveillance of TB patients, even in settings with high DM incidence.

Methods

Study participant recruitment, classification and treatment

Adult pulmonary TB patients were recruited as part of the TANDEM project²⁹ in two locations: Bandung in Indonesia (UNPAD) and Cape Town in South Africa (SUN). All TB patients were newly diagnosed and microbiologically confirmed, and included people with TB-DM. The TB-DM group included participants with both pre-diagnosed DM and newly identified DM, with new diagnosis based on a laboratory HbA1c test $\geq 6.5\%$ with a confirmatory HbA1c test $\geq 6.5\%$ or fasting blood glucose ≥ 7 mmol/L at TB diagnosis²⁹, followed by a further HbA1c test $\geq 6.5\%$ after 6 months of TB treatment. The TB patients without DM included people with a normal glycaemic index (laboratory HbA1c $< 5.7\%$) at TB diagnosis (“TB-only”). Patients whose HbA1c test results were $\geq 5.7\%$ and $< 6.5\%$ at both TB diagnosis and at 6 months were deemed to have pre-diabetes (“TB-preDM”) and patients with raised glycaemia at TB diagnosis but below the cut-off for DM diagnosis ($5.7\% \leq$ laboratory HbA1c $< 6.5\%$) were deemed to have TB-related intermediate hyperglycaemia (“TBrel-IH”). In South Africa, healthy controls without TB or DM were also recruited for baseline sample analysis. Multi-drug-resistant TB, HIV positivity, pregnancy, serious co-morbidity and corticosteroid use were exclusion criteria.

TB patients received standard first line TB treatment according to WHO Guidelines. Microbiological measures recorded at baseline and throughout treatment included sputum smear and culture, with time to positivity (TTP) in mycobacteria growth indicator tubes (MGIT) also assayed in South Africa. TB patients were classified based on their treatment outcome: “poor treatment outcome” included those patients who died, failed initial treatment (remained sputum positive at five months) or experienced TB-recurrence in the 12 month

follow-up period post treatment, whilst those with “good treatment outcome” had successful TB treatment without subsequent recurrence. Patients for whom the outcome data were missing were not included in downstream analyses. Most TB-DM patients received local standard of care DM treatment, whilst a subgroup in Indonesia received more intensive HbA1c monitoring and treatment adjustment through TB treatment as part of a pragmatic randomised control trial.³⁴

Ethics Statement

The study was approved by the London School of Hygiene & Tropical Medicine Observational Research Ethics Committee (6449), the SUN Health Research Ethics Committee (N13/05/064) and the UNPAD Health Research Ethics Committee, Faculty of Medicine, Universitas Padjadjaran (number 377/UN6.C2.1.2/ KEPK/ PN), and participants gave written informed consent.

RNA sample collection and extraction

Patient samples were collected prior to initiation of treatment (diagnosis), at weeks 2, 4, 8, 16 and 26 through treatment, and at 12 months after TB diagnosis, and from HC at baseline only. Venous blood (2.5ml) was collected into PAXgene Blood RNA Tubes (PreAnalytiX). Total RNA was extracted using RNeasy spin columns (Qiagen) and quantified by Nanodrop (Agilent). The LabChip GX HiSens RNA system (PerkinElmer) was used for quality assessment of samples processed by RNA-Seq.

Unbiased RNA-Seq of global gene expression

Samples collected at TB diagnosis and weeks 2, months 2, and months 6 from the first 63 participants recruited were analysed by RNA-Seq (Table 1). Libraries were generated using the poly-A tail Bioscientific NEXTflex-Rapid-Directional mRNA-Seq method with the Caliper SciClone. Single-end sequencing was performed using the NextSeq500 High Output kit V2

(Illumina) for 75 cycles. Sequence data from FASTQ files were aligned to the Human g1kv37 reference genome, using STAR (v2.5.1b).³⁵ Quality control was performed with FastQC³⁶, while transcript quantification was performed using HT-seq count (v0.61)³⁷: lowly expressed transcripts (<50 counts across all samples), were removed from the downstream analysis. RNA-Seq data were normalised using DESeq2 (v1.30.0).³⁸

Dual-color Reverse-Transcriptase Multiplex Ligation-dependent Probe Amplification (dcRT-MLPA)

Dual-color reverse-Transcriptase Multiplex Ligation-dependent Probe Amplification (dcRT-MLPA) was performed on all samples to identify blood transcriptional profiles as described previously.³⁹ Brief descriptions are provided in the Supplementary Information. RT primers and half-probes were designed by Leiden University Medical Centre (LUMC, Leiden, The Netherlands) and encompassed sequences for 144 selected key immune-related genes to profile the innate, adaptive and inflammatory immune responses (Supplementary Table S1), and four housekeeping genes (*GAPDH*, *ABR*, *GUSB*, *B2M*). Genes with an adjusted p-value <0.05 (Benjamini-Hochberg⁴⁰) and a log2-fold change (FC) <-0.6 and >0.6 were considered differentially expressed genes (DEGs). Genes that were below the detection limit in >90% of the samples per cohort were excluded from analysis.

Data analysis and Statistics

Statistical analyses to compare participant demographics were carried out using GraphPad Prism 8 software (Graphpad Software, San Diego, CA, USA). For continuous measures, a Mann-Whitney U-test was used when comparing two groups and a Kruskal-Wallis test when comparing three groups. For non-continuous measures, the Chi-square test was used. P-values as <0.05 were considered significant.

Molecular Degree of Perturbation (MDP) analysis was performed by R using *mdp* R package⁴¹, and differences between the mean ranks of the groups were assessed by Mann-Whitney U test followed by Benjamini-Hochberg False discovery correction.⁴⁰ Cell population estimates were calculated using the *cellCODE*⁴² R package, with the *IRIS*⁴³ and *DMAP*⁴⁴ data sets used as a reference. Modular analysis was performed using the R package *tmod*⁴⁵ and its *HGtest* method, with DEGs used as the foreground and all genes used as the background signal.

Differential expression analysis (DEA) was performed in R using the *MaSigPro* package⁴⁶ to characterise longitudinal differential gene expression of genes measured by RNA-Seq: this followed a two-step regression method, finding genes with significant temporal expression changes and also significant differences between clinical groups. A quadratic regression model was executed due to the number of timepoints analysed. The regression model treats time as a quantitative variable so differentially expressed are not only detected, but also changes in trends and magnitude.

Longitudinal DEA of genes measured by dcRT-MLPA was assessed by means of linear mixed models for repeated measures over time using *lme4* package in R.⁴⁷ A Benjamini-Hochberg False discovery correction was performed, with an adjusted p-value of <0.05 deemed significant. Non-parametric Mann-Whitney U-test followed by Benjamini-Hochberg correction was performed to identify DEGs between patients who had a good and poor treatment outcome. Correlations were evaluated using Pearson's correlation coefficient.

Treatment outcome signatures based on dcRT-MLPA data were identified in TB patients of South Africa and Indonesia using Recursive Feature Elimination (RFE)⁴⁸ and Random Forest (RF). Because the number of patients with a good treatment outcome was considerably larger than those with a poor treatment outcome (poor, n=38; good, n=134), a random down-sampling technique as well as a Synthetic Minority Oversampling Technique

(SMOTE) were applied to balance the classes (i.e. “good treatment outcome” and “poor treatment outcome”) of the dataset.⁴⁹ RF was performed as machine learning algorithm on the dataset including the selected genes and the performance of gene signatures was evaluated by Leave-One-Out Cross Validation (LOOCV).^{50,51} We assessed the classifying performance of the model by evaluating Receiver Operating Characteristic (ROC) curve and Area Under the ROC Curve (AUC) with 95% Confidence Interval (CI). An extended description of the data-analysis methods is provided in the Supplementary Information.

Role of Funders

Funders had no role in study design, data collection, data analyses, data interpretation, writing of the report and decision to submit the paper for publication.

Results

Study Design and Cohort

Pulmonary TB patients were recruited into the prospective longitudinal study in South Africa and Indonesia, and followed up through standard treatment and for the following 12 months. Altogether, 39 TB patients of the 176 recruited had a “poor treatment outcome”, with 7 patients dying, 26 failing treatment (based on continued sputum smear or culture positivity at month 6), and 6 experiencing recurrences in the subsequent 18 months. The “poor treatment outcome” rates were similar in the two sites (Table 1). The median age of the patients was equal in patients with either a good or poor treatment outcome (median = 47 years), with a higher proportion of males with a poor treatment outcome than a good treatment outcome (56% and 67% respectively). The proportion of TB patients with DM with a poor treatment outcome (15/39; 38%) was slightly higher than that with a good treatment outcome (44/137; 32%),

whereas the proportion with TBrel-IH was higher in those with a good treatment outcome (65/137; 47%) than a poor treatment outcome (14/39; 36%). There was no evidence that those who had a poor treatment outcome had more severe TB at diagnosis, with similar sputum bacterial loads (as measured by TTP) in TB patients from South Africa and similar sputum smear grade in Indonesia across the good and poor treatment outcome groups.

Poor treatment outcome was reflected by an attenuated treatment response compared to good treatment outcome

The holistic unbiased analysis of gene expression in TB patients with good or poor treatment outcomes by RNA-Seq approach was performed on a subset of study participants (Table 1). There were significant changes in global gene expression in patients with a good treatment outcome continuously through TB treatment, reflecting treatment response (Figure 1A). Gene expression perturbation was also evident in patients who had a poor treatment outcome, although the sample score was higher at diagnosis compared to patients who had a good treatment outcome. This represents differences at the transcriptomic level between patients with a good versus a poor treatment outcome, already before initiation of anti-TB treatment. This was followed by less change over time in response to TB treatment in the poor TB outcome group.

Next, we focused our molecular distance analysis on 144 TB-associated genes as measured by dcRT-MLPA, which was performed on all study participants (n=201) (Table 1). Again, there were significant changes in global gene expression continuously through TB treatment in patients with a good treatment outcome, but not in patients with a poor treatment outcome (Figure 1B), reflecting an attenuated TB treatment response. Despite the substantial treatment response in patients who had a good treatment outcome, gene expression perturbation did not completely normalize to levels of healthy controls by 6 months (Supplementary Figure S1).

Together, these data suggest that there was a different biosignature in those with good versus poor treatment outcomes, which was reflected by transcriptomic differences before initiation of anti-TB treatment and by a tempered response to anti-TB treatment in patients with a poor treatment outcome compared to patients with a good treatment outcome.

Global Differential expression in patients who had good or poor responses to TB treatment

The changes in gene expression in the RNA-Seq data through time and between the patients with a good or poor treatment outcome were analyzed by MaSigPro, initially in the South African and Indonesian cohorts separately. The strength in this method was that it was able to monitor the change in dynamics over time and also between different treatment groups. In South Africa, the genes which changed differently through time between the patients with good or poor treatment outcome were grouped into nine clusters (Supplementary Figure S2A, Supplementary Table S2), with an increase in expression through treatment in four clusters (1,2,3,5), a decrease in four clusters (4,6,7,8), and no change in one cluster (9). Genes with higher expression throughout treatment in TB patients with poor treatment outcome were grouped in seven clusters (1,3,4,5,7,8,9) and those with higher expression in TB patients with a good treatment outcome were grouped in two clusters (2,6). A similar pattern was observed in the Indonesian cohort, with DEGs identified through treatment between good and poor separating into nine clusters (genes increasing in clusters 2,5,7, and decreasing in clusters 1,3,4,6,8,9) (Supplementary Figure S2B, Supplementary Table S3), with higher expression in either the good or poor treatment outcome group. Importantly, these differences in gene expression through time were observed in all TB patient groups, irrespective of their DM status.

The genes grouped into the clusters in the Indonesian and South African cohorts partially overlapped but there was variability. A third MaSigPro analysis was therefore conducted, to find those genes which were differentially expressed through treatment between TB patients with a good or poor treatment outcome, irrespective of their geographical origin

(Figure 2, Supplementary Table S4). Again, the genes differentially expressed through treatment in the combined analysis separated into nine clusters, with variable patterns of expression over time and between TB patients with good or poor treatment outcome. Some clusters (2,5,6) contained genes which were different between the groups at all time points, whereas other clusters (1,3,4,5,7,8,9) were similar at some timepoints and more divergent at others (Figure 2, Table 2).

The number of transcripts within each cluster in the combined analysis ranged from 4 to 47 (Table 2), with the majority of genes identified in all clusters encoding proteins. There were also various regulatory transcripts in some clusters, including long non-coding RNAs, miRNA, snoRNA, retained introns, as well as antisense, nonsense-mediated decay, overlapping senses and sense intronic transcripts. To understand the biological function of the DEGs, the transcripts within each cluster were analysed using the g:COST tool within the g:Profiler application⁵², to determine significant enrichment of genes in Gene Ontology (GO) molecular function, cellular component and biological process categories, as well as in curated biological pathways from KEGG and Reactome databases and the CORUM protein database. Genes in cluster 2 were largely involved in B cell receptor signalling, seen in the GO and pathway analyses, and these were more highly expressed in people who had a poor treatment outcome, with increasing expression through treatment. This upregulation of genes involved in B cell function, particularly those involved in earlier stages of B cell development, was not related to the overall number of B cells in the samples, as predicted from the samples using CellCode analysis package (Supplementary Figure S3). Cluster 9 was predominantly composed of immunoglobulin transcripts, whose expression decreased much more substantially in patients with a good treatment outcome. The largest gene cluster (4) was enriched with genes involved in actin remodelling, including the Arp 2/3 complex, and in pathways related to infections with bacteria such as *Shigella*, *E. coli*, *Yersinia* and *Salmonella*.

Cluster 7 contained genes related to mitotic cell division, and these were more highly expressed in patients with a poor treatment outcome (Table 2). These analyses were also performed using the DAVID online tool⁵³, and similar results were obtained (not shown). The DEGs found in the combined and separate cohort MaSigPro analyses were used as a foreground against all genes in a modular analysis using the Tmod package, which gives biological function to a gene list. It showed an upregulation of genes involved in B cell function in good versus poor treatment outcomes, in both the Indonesian and South African cohorts (Supplementary Table S5).

Identification of DEGs through TB treatment in patients with good or poor treatment outcomes

Next, we focused our DEA on 144 genes that previously have been associated with TB³⁹ using dcRT-MLPA (Supplementary Table S6). No significant DEGs were detected by directly comparing patients with a good versus a poor treatment outcome at the indicated timepoints (Supplementary Figure S4), and therefore we analyzed longitudinal expression of genes. Kinetic profiling of DEGs identified 16 DEGs in patients with a good treatment outcome and 12 DEGs in patients with a poor treatment outcome. The longitudinal expression of DEGs identified by dcRT-MLPA showed a significant correlation with genes measured by RNA-Seq, highlighting the validity and reproducibility of our approach (Supplementary Figure S5). A high correlation between DEGs of patients who had a poor treatment outcome and DEGs of patients who had a good treatment outcome could be detected ($R=0.87$, $p<0.0001$), highlighting the challenge of discriminating patients with a good versus a poor treatment outcome based on single genes (Supplementary Figure S6). Genes associated with active TB^{15,20,54} or risk of developing TB²² were substantially downregulated (*GBP1*, *GBP2*, *GBP5*, and *IFITM3*) or upregulated (*GPLY* and *PRF1*) over time in TB patients regardless of their treatment outcome, reflecting transcriptomic response to anti-TB treatment (Figure 3A and

Supplementary Figure S7). Other genes associated with active TB were significantly down- or upregulated (*STAT2*, *MMP9*, *IRF7*, *IFI6*, *IFIT2*, *IFIT3*, and *CCR7*) during anti-TB treatment in patients who had a good treatment outcome, but not in patients who had a poor treatment outcome, or vice versa (*CD3E*, *PTPRCv1*, *NLRP1*, *BCL2*)^{15,39,54,55}. The expression of *TAGAP*, previously associated with active TB⁵⁵, was significantly increased during anti-TB treatment in patients who had a poor treatment outcome. Modular analysis showed that the gene profile of regulated genes was dominated by genes in the interferon (IFN) signaling pathway, especially in patients who had a good treatment outcome (Figure 3B).

Identification of a signature predicting treatment outcome

Machine learning algorithms were implemented on data obtained at each time point to develop biomarker panels to predict treatment outcomes at different stages of TB treatment. First, we aimed to identify gene signatures from RNA-Seq analysis on a subset of subjects, but we found a low performance of gene signatures generated on diagnosis, week two and month six (AUC=0.625, AUC=0.667 and AUC=0.615, respectively) to predict treatment outcome, potentially due to a low number of patients in the training and test set (Supplementary Figure S8A). The best performing model was built on month two resulting in an AUC of 0.8667 (Supplementary Figure S8A, Supplementary Table S7). We also tested an active TB disease biomarker signature, namely the three-gene Sweeney signature²⁰, to determine whether it resolved significantly more in those with a good treatment outcome than in those with a poor treatment outcome. This signature has previously been shown to persist in patients with persistent lung inflammation²⁶. However, in our RNA-Seq data, this signature revealed an AUC of 0.5333 (Supplementary Figure S8B) highlighting that the process behind poor treatment outcome cannot be predicted by expression of these three genes.

Next, we aimed to identify early correlates of treatment outcome by implementing machine learning algorithms on gene expression as measured by dcRT-MLPA. We focused

our analysis on the identification of gene predictors at diagnosis and at week two that could possibly be used in future studies to predict the occurrence of poor or good treatment outcome before or early after anti-TB treatment initiation, first by down-sampling the good treatment outcome class. The top eight ranked genes (*GBP1*, *FCGR1A*, *STAT1*, *IFITM3*, *BCL2*, *CCL4*, *TLR9*, *CD274*) from the diagnosis signature were used for RF machine learning model implementation (Table 3). Excitingly, the signature had a high predictive power (AUC=0.815) to classify TB patients with a good or poor treatment outcome, already before anti-TB treatment initiation (Figure 4A). Furthermore, the gene signature showed high performance on the cohorts separately (South Africa, AUC=0.845; Indonesia, AUC=0.744). Next, we investigated whether accuracy could be improved by predicting treatment outcome after initiation of anti-TB treatment, thus measuring the early treatment response. We identified a 22-gene signature to predict treatment outcome at two weeks after initiation of anti-TB treatment (Table 3). The performance of the week two signature in predicting treatment outcome was slightly improved (AUC=0.834) compared to the diagnosis signature, especially in patients from the Indonesian cohort (AUC=0.867 versus AUC=0.744 at diagnosis). Furthermore, we identified a 14-gene month two signature, which, however, demonstrated a slightly lower accuracy in predicting treatment outcome compared to diagnosis and week two gene signatures (AUC=0.791).

Since we detected differences in the kinetics of gene expression of patients who had a good treatment outcome versus patients with a poor treatment outcome (Figure 1), we next assessed whether a “delta” gene signature, by subtracting week two values from diagnosis, could improve the predictive performance. The delta signature encompassed seven genes (*GNLY*, *MRC1*, *GBP5*, *NLRP1*, *FLCN1*, *ZNF532*, and *IFIT2*) and slightly improved predictive performance (pooled cohorts, AUC=0.849; South Africa, AUC=0.839 and Indonesia, AUC=0.872) compared to the week two and diagnosis signatures (Supplementary Figure S9, Supplementary Table S8). Multiple genes were included in more than one gene signature

(Supplementary Figure S10A), of which four genes (*GBP1*, *GBP5*, *FCGR1A*, *INDO*) are shown in Figure 4B. Next, we validated performance of the diagnosis signature and month two signature on an independent validation cohort²⁸, which like our cohorts, included diabetic patients. Our diagnosis gene signature had high predictive power on the Indian validation cohort (AUC=0.749) (Figure 4C). The week two and delta signatures could not be validated on the Indian cohort, because samples were not collected two weeks after initiation of anti-TB treatment in this cohort. Three genes (*CD3E*, *PTPRCv1*, *NOD2*) that were included in our gene signatures, were also part of gene signatures described by Sivakumaran et al. (Supplementary Figure S10B). Finally, we assessed whether gene signatures with improved performance could be obtained by applying SMOTE⁴⁹ as an alternative sampling technique. A diagnosis SMOTE gene signature was obtained that showed overlap with the diagnosis gene signatures obtained by random down-sampling (Supplementary Table S9, Supplementary Figure S10C). The SMOTE signature produced a high degree of accuracy in discriminating patients with a good treatment outcome from patients with a poor treatment outcome, but performed with lower accuracy compared to the diagnosis signature obtained by random down-sampling (pooled cohorts, AUC=0.728; South Africa, AUC=0.695; Indonesia, AUC=0.765) (Supplementary Figure S11). The diagnosis SMOTE signature exerted a similar predictive capacity on the external Indian cohort compared to the down-sampling signature (SMOTE, AUC=0.704; down-sampling, AUC=0.749).

Taken together, we identified gene signatures with high predictive power on treatment outcome, irrespective of DM as comorbidity, in patients from South Africa and Indonesia and in patients from the external Indian validation cohort.

Discussion

In this study, we identified peripheral blood transcriptional signatures which predict anti-TB treatment success and failure in TB patients with or without concomitant hyperglycaemia or DM. Previous studies developing biomarker signatures of TB treatment success, recurrence or failure^{24-26,56} did not include people with DM comorbidity, and we have previously found concomitant DM impairs existing TB diagnosis signature accuracy.³² Here we showed DM also affects existing TB treatment-response biomarker signatures in the RNA-Seq dataset, suggesting that they should be derived with cohorts including this population.

Our whole cohort dataset, from which we generated treatment outcome signatures, was derived using our dcRT-MLPA gene set, which did not contain most of the genes reported in previous signatures, except *GBP5*, which was included in our week two and month two gene signatures. Sivakumaran et al.²⁸ recently reported baseline and month two gene signatures predicting treatment outcome at six months after initiation of anti-TB treatment, using the same material (whole blood), technique (dcRT-MLPA) and gene set. Notably, our treatment outcome gene signatures showed some overlap with the signatures reported by Sivakumaran et al. (*CD3E*, *PTPRCv1*, *NOD2*), suggesting that these genes are useful in predicting treatment outcome independently of ethnical background. Furthermore, our treatment outcome gene signatures showed overlap of genes of the TB risk signature predicting TB progression from healthy controls more than a year before onset of TB (*GBP1*, *GBP2*, *GBP5*, *FCGR1A*, *STAT1*, *TAP1*).²² Within our study, 12 genes (*BCL2*, *BMP6*, *CCL13*, *CD209*, *FCGR1A*, *GBP1*, *GBP5*, *INDO*, *MMP9*, *MRC1*, *STAT1*, *TLR9*) were overlapping between gene signatures, including both the gene signatures obtained by down-sampling and the gene signatures obtained by SMOTE. The occurrence of genes in multiple gene signatures within this study and between studies highlights the power of transcriptomic biomarkers in predicting treatment outcome and

suggests that universal biomarkers can be applied to cohorts of different ethnicity and independently of the DM/glycaemia status of TB patients.

Patients with a poor treatment outcome responded to anti-TB treatment at the level of individual genes, as detected by downregulation of genes (*GBP1*, *GBP2*, *GBP5*, *IFITM3*) that have been associated with active TB and upregulation of genes (*CD3E*, *PTPRCv1*, *NLRP1*, *GNLY*, *PRF1*, *BCL2*) that show lower expression in patients with active TB compared to LTBI or healthy controls^{15,20,39,55}. However, MDP analysis showed that the response to anti-TB treatment was diminished in those with a poor treatment outcome compared to patients who had a good treatment outcome. Notably, the majority of genes that were significantly downregulated in patients who had a good treatment outcome, but not in patients who had a poor treatment outcome, are involved in IFN signaling (*IRF7*, *IFIT2*, *IFIT3*, *STAT2*, *IFI6*, *TAP2*). This suggests that a poor treatment outcome was reflected by persisting IFN signaling response and supports a role for type I IFN signaling in TB pathogenesis.^{15,57}

TAGAP was significantly increased in patients who had a poor treatment outcome in the pooled South African and Indonesian cohort as well as in both cohorts separately. *TAGAP* encodes T-cell activation Rho-GTPase-activating protein, however, the exact role of *TAGAP* in *Mtb* pathogenesis is currently unknown. Several studies have linked *TAGAP* with active TB; *TAGAP* was enriched for differential acetylation peaks upon *Mtb* infection in granulocytes⁵⁸ and *TAGAP* was induced upon vaccination with AERAS-402 vaccine encoding a fusion protein of *Mtb* antigens.⁵⁹ Furthermore, *TAGAP* had higher expression in TB patients compared to LTBI and healthy controls⁵⁵ and, surprisingly, lower expression in pulmonary TB compared to household controls.⁶⁰ Our data showing that *TAGAP* expression was significantly increased during anti-TB treatment in patients who had a poor treatment outcome could indicate that *TAGAP* is actively involved in TB pathogenesis or that *TAGAP* expression is a consequence of persisting *Mtb* infection, but this remains to be investigated.

There are several limitations of the current study. First, the sample size in this study was not based on an a priori power calculation, as this study was part of a larger study investigating differences in gene expression in patients with varying degrees of hyperglycemia. To increase statistical power, we therefore pooled patients from two cohorts (South Africa and Indonesia), which introduced heterogeneity within the studied groups. However, this can also be a strength, potentially increasing application over different ethnic backgrounds. Second, there were missing values in the cohort study. The missing values occurred as a result of random drop-outs or technical errors caused by low quantity or quality of some samples, and therefore the use of linear mixed models for the DEA most likely produced unbiased results. Third, although the prevalence of hyperglycaemia/DM is not indicated in the majority of other TB biomarker studies, which is a limitation of these studies considering the rising incidence of TB-DM comorbidity, our study contained many patients with high HbA1c levels. Although this may have introduced a bias, the strength of this approach is that treatment outcome signatures have been developed that can be applied to patients independently of their glycaemia/DM status. Furthermore, we showed that our eight-gene diagnosis signature had a high performance (AUC=0.749) when tested on an external validation cohort in patients with a different ethnic background (India), which is striking since geographic or ethnic variations may significantly impact on the immune responses to TB.

In this study, we demonstrated the potential of gene signatures to predict treatment outcome, in a cohort including patients with concomitant DM or hyperglycaemia. Identification of a diagnosis gene signature containing only eight genes in this study, and even fewer genes in signatures reported by others^{26,27}, indicates that clinically-implementable biomarker signatures can be developed using transcriptomic-based approaches using easily accessible whole blood, and that are promising as surrogate marker for sputum culture conversion.

Contributors

Study concept and design: BA, RvC, RR, PCH, GW, SAJ, JAC, MCH, HMD, THMO, JMC;
Patient recruitment, Sample collection, processing and selection: BA, KR, STM, LK, PCH, KS, RR, GW; Clinical database design, curation, maintenance: SK-B, JAC;
Laboratory Experiments and data acquisition: CE, SvV, JSL, JMC; Data Analysis and interpretation: CLRVd, CE, SvV, VK, SAJ, CW, MCH, HMD, THMO, EV, JMC; Writing the manuscript: CLRVd, CE, SAJ, HMD, THMO, EV, JMC; Critical Revision of the manuscript: CLRVd, CE, KR, STM, SAJ, PCH, JAC, MCH, HMD, THMO, EV, JMC; All authors read and approved the final version of the manuscript.

Declaration of Interests

GW had patents to methods of tuberculosis diagnosis and to tuberculosis biomarkers unrelated to the current study. The rest of the authors declare no financial or commercial conflicts of interest.

Acknowledgements

The authors acknowledge all participants involved in this study. The authors acknowledge Bahram Sanjabi, Desiree Brandenburg-Weening, and Pieter van der Vlies for assistance with the RNA-Seq, Evelien Temminck for providing technical assistance with dcRT-MLPA experiments, Erni Durdevic for providing statistical and machine learning advice, and Prof. Dr. Harleen Grewal and Dr. Dhanasekaran Sivakumaran for providing datafiles of the cross-validation dataset.

Data Sharing Statement

RNA sequence data have been submitted to NCBI Gene Expression Omnibus (GEO) under accession number GSE193979. dcRT-MLPA data can be found in Supplementary Table S6.

References

1. World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO., 2021.
2. Alemu MA, Yesuf A, Girma F, et al. Impact of HIV-AIDS on tuberculosis treatment outcome in Southern Ethiopia—A retrospective cohort study. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases* 2021; **25**: 100279.
3. Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. *Int J Tuberc Lung Dis* 2019; **23**(7): 783-96.
4. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. *PLoS med* 2008; **5**(7): e152.
5. Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. *BMC medicine* 2011; **9**(1): 1-15.
6. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. *The American journal of tropical medicine hygiene* 2009; **80**(4): 634.
7. Alisjahbana B, Sahiratmadja E, Nelwan EJ, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. *Clinical Infectious Diseases* 2007; **45**(4): 428-35.
8. Tuomilehto J. The emerging global epidemic of type 1 diabetes. *Current diabetes reports* 2013; **13**(6): 795-804.
9. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. *Diabetes research and clinical practice* 2019; **157**: 107843.
10. Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. *The Lancet infectious diseases* 2010; **10**(6): 387-94.
11. Bhat J, Rao V, Muniyandi M, Yadav R, Karforma C, Luke C. Impact of sputum quality and quantity on smear and culture positivity: findings from a tuberculosis prevalence study in central India. *Transactions of the Royal Society of Tropical Medicine Hygiene* 2014; **108**(1): 55-6.
12. Hernández P, Punchak M, Camacho M, Hepple P, McNerney R. Investigating the quality of expectorated sputum for tuberculosis diagnosis in Bolivia. *The International Journal of Tuberculosis and Lung Disease* 2015; **19**(9): 1065-7.
13. Meyer AJ, Atuheire C, Worodria W, et al. Sputum quality and diagnostic performance of GeneXpert MTB/RIF among smear-negative adults with presumed tuberculosis in Uganda. *PLoS One* 2017; **12**(7): e0180572.
14. Warsinske H, Vashisht R, Khatri P. Host-response-based gene signatures for tuberculosis diagnosis: A systematic comparison of 16 signatures. *PLoS medicine* 2019; **16**(4): e1002786.
15. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. *Nature* 2010; **466**(7309): 973-7.
16. Bloom CI, Graham CM, Berry MP, et al. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. *PloS one* 2012; **7**(10): e46191.
17. Cliff JM, Lee JS, Constantinou N, et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. *J Infect Dis* 2013; **207**(1): 18-29.
18. Kaforou M, Wright VJ, Oni T, et al. Detection of tuberculosis in HIV-infected and-uninfected African adults using whole blood RNA expression signatures: a case-control study. *PLoS Med* 2013; **10**(10): e1001538.
19. Maertzdorf J, McEwen G, Weiner 3rd J, et al. Concise gene signature for point-of-care classification of tuberculosis. *EMBO molecular medicine* 2016; **8**(2): 86-95.
20. Sweeney TE, Braviak L, Tato CM, Khatri P. Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis. *The Lancet Respiratory Medicine* 2016; **4**(3): 213-24.

21. Scriba TJ, Penn-Nicholson A, Shankar S, et al. Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. *PLoS Pathog* 2017; **13**(11): e1006687.
22. Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. *The Lancet* 2016; **387**(10035): 2312-22.
23. Mistry R, Cliff JM, Clayton CL, et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. *J Infect Dis* 2007; **195**(3): 357-65.
24. Cliff JM, Cho J-E, Lee J-S, et al. Excessive cytolytic responses predict tuberculosis relapse after apparently successful treatment. *The Journal of infectious diseases* 2016; **213**(3): 485-95.
25. Thompson EG, Du Y, Malherbe ST, et al. Host blood RNA signatures predict the outcome of tuberculosis treatment. *Tuberculosis* 2017; **107**: 48-58.
26. Warsinske HC, Rao AM, Moreira FM, et al. Assessment of validity of a blood-based 3-gene signature score for progression and diagnosis of tuberculosis, disease severity, and treatment response. *JAMA network ope* 2018; **1**(6): e183779-e.
27. Suliman S, Thompson EG, Sutherland J, et al. Four-gene pan-African blood signature predicts progression to tuberculosis. *American journal of respiratory and critical care medicine* 2018; **197**(9): 1198-208.
28. Sivakumaran D, Jenum S, Vaz M, et al. Combining host-derived biomarkers with patient characteristics improves signature performance in predicting tuberculosis treatment outcomes. *Communications Biology* 2020; **3**(1): 359.
29. Ugarte-Gil C, Alisjahbana B, Ronacher K, et al. Diabetes mellitus among pulmonary tuberculosis patients from 4 tuberculosis-endemic countries: the TANDEM study. *Clinical Infectious Diseases* 2020; **70**(5): 780-8.
30. Viswanathan V, Kumpatla S, Aravindalochanan V, et al. Prevalence of diabetes and pre-diabetes and associated risk factors among tuberculosis patients in India. *PLoS One* 2012; **7**(7): e41367.
31. Restrepo BI, Camerlin AJ, Rahbar MH, et al. Cross-sectional assessment reveals high diabetes prevalence among newly-diagnosed tuberculosis cases. *Bulletin of the World Health Organization* 2011; **89**: 352-9.
32. Eckold C, Kumar V, Weiner J, et al. Impact of Intermediate Hyperglycemia and Diabetes on Immune Dysfunction in Tuberculosis. *Clinical Infectious Diseases* 2021; **72**(1): 69-78.
33. Prada-Medina CA, Fukutani KF, Kumar NP, et al. Systems immunology of diabetes-tuberculosis comorbidity reveals signatures of disease complications. *Scientific reports* 2017; **7**(1): 1-16.
34. Ruslami R, Koesoemadinata RC, Soetedjo NNM, et al. The effect of a structured clinical algorithm on glycemic control in patients with combined tuberculosis and diabetes in Indonesia: A randomized trial. *Diabetes Research and Clinical Practice* 2021; **173**: 108701.
35. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 2013; **29**(1): 15-21.
36. Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010. <http://www.bioinformatics.babraham.ac.uk/projects/fastqc2020>.
37. Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. *bioinformatics* 2015; **31**(2): 166-9.
38. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome biology* 2014; **15**(12): 1-21.
39. Joosten S, Goeman J, Sutherland J, et al. Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay. *Genes & Immunity* 2012; **13**(1): 71-82.
40. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal statistical society: series B (Methodological)* 1995; **57**(1): 289-300.
41. Lever M RP, Nakaya H. mdp: Molecular Degree of Perturbation calculates scores for transcriptome data samples based on their perturbation from controls. R package version 1.12.0. 2021. <https://mdp.sysbio.tools/>.

42. Chikina M, Zaslavsky E, Sealfon SC. CellCODE: a robust latent variable approach to differential expression analysis for heterogeneous cell populations. *Bioinformatics* 2015; **31**(10): 1584-91.
43. Abbas AR, Wolslegel K, Seshasayee D, Modrusan Z, Clark HF. Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. *PLoS one* 2009; **4**(7): e6098.
44. Novershtern N, Subramanian A, Lawton LN, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. *Cell* 2011; **144**(2): 296-309.
45. Weiner 3rd J, Domaszewska T. tmod: an R package for general and multivariate enrichment analysis. *PeerJ Preprints* 2016; **4**: e2420v1.
46. Nueda MJ, Tarazona S, Conesa A. Next maSigPro: updating maSigPro bioconductor package for RNA-seq time series. *Bioinformatics* 2014; **30**(18): 2598-602.
47. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *arXiv preprint arXiv:1406.5823* 2014.
48. Gregorutti B, Michel B, Saint-Pierre P. Correlation and variable importance in random forests. *Statistics and Computing* 2017; **27**(3): 659-78.
49. Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. SMOTE: synthetic minority over-sampling technique. *Journal of artificial intelligence research* 2002; **16**: 321-57.
50. Liaw A, Wiener M. Classification and regression by randomForest. *R news* 2002; **2**(3): 18-22.
51. Kuhn M. Building predictive models in R using the caret package. *Journal of statistical software* 2008; **28**(1): 1-26.
52. Raudvere U, Kolberg L, Kuzmin I, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). *Nucleic Acids Research* 2019; **47**(W1): W191-W8.
53. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic acids research* 2009; **37**(1): 1-13.
54. Gebremicael G, Kassa D, Quinten E, et al. Host gene expression kinetics during treatment of tuberculosis in HIV-coinfected individuals is independent of highly active antiretroviral therapy. *The Journal of infectious diseases* 2018; **218**(11): 1833-46.
55. Gebremicael G, Kassa D, Alemayehu Y, et al. Gene expression profiles classifying clinical stages of tuberculosis and monitoring treatment responses in Ethiopian HIV-negative and HIV-positive cohorts. *PLoS One* 2019; **14**(12): e0226137.
56. Heyckendorf J, Marwitz S, Reimann M, et al. Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. *European respiratory journal* 2021.
57. Moreira-Teixeira L, Mayer-Barber K, Sher A, O'Garra AJJoEM. Type I interferons in tuberculosis: Foe and occasionally friend. *J Journal of Experimental Medicine* 2018; **215**(5): 1273-85.
58. del Rosario RCH, Poschmann J, Kumar P, et al. Histone acetylome-wide association study of tuberculosis. *bioRxiv* 2019: 644112.
59. Sivakumaran D, Blatner G, Bakken R, et al. A 2-Dose AERAS-402 Regimen Boosts CD8+ Polyfunctionality in HIV-Negative, BCG-Vaccinated Recipients. *Frontiers in Immunology* 2021; **12**: 2141.
60. Sivakumaran D, Ritz C, Gjølven JE, et al. Host blood RNA transcript and protein signatures for sputum-independent diagnostics of tuberculosis in adults. *Frontiers in immunology* 2020; **11**: 3795.

664 Tables

665 **Table 1. Study Participant Demographics**

Characteristic	Country	TB Patients		Healthy Controls	P-value
		Good Outcome	Poor Outcome		
Total Number of Participants	S Africa	76	18	27	-
	Indonesia	61	21	0	-
	All	137	39	27	-
Age in years, median (range)	S Africa	46 (22-68)	42 (19-55)	42 (30-70)	0.485
	Indonesia	49 (25-73)	49 (35-68)	-	0.96
	All	47 (22-73)	47 (19-68)	42 (30-70)	0.2801
Sex, % male (No. male/ female)	S Africa	58 (44/32)	67 (12/6)	52 (14/13)	0.6981
	Indonesia	53 (32/29)	67(14/7)	-	0.3136
	All	56 (76/61)	67 (26/13)	52 (14/13)	0.2704
Number with Diabetes / Intermediate Hyperglycaemia / Normal glycaemia (%)	S Africa	13/49/14	4/11/3	0/0/27	0.8775 ^s
	Indonesia	31/16/14	11/3/6	-	0.5589
	All	44/65/28	15/14/9	0/0/27	0.5409^s
HbA1c median (range)	S Africa	6.0 (4.9-14.3)	6.0 (4.8-14.1)	5.3 (4.8-6.4)	0.6144 ^s
	Indonesia	8.15 (4.9-17.1)	7.1 (5.1-14.1)	-	0.5612
	All	6.0 (4.9-17.1)	6.1 (4.8-14.1)	5.3 (4.8-6.4)	0.9892^s
BMI at TB diagnosis:, median (range)	S Africa	18.7 (13.9-32.3)	18.3 (13.7-31.2)	23.7 (17.4-45.2)	0.9588 ^s
	Indonesia	19.7 (13.8-33.3)	18.8 (16.3-27.3)	-	0.8433
	All	19.1 (13.8-33.3)	18.8 (13.7-31.2)	23.7 (17.4-45.2)	0.8351^s
TTP (days) at TB diagnosis: Median (range) (missing values)	S Africa	6 (1-21) (18)	6 (3-21) (3)	N/A	0.8916
Smear Grade at diagnosis number: 3+/2+/1+/-scanty/negative	Indonesia	16/23/14/2/6	8/4/6/2/1	N/A	0.3637
Sputum conversion at Month 2: number yes/no (missing values)	S Africa	49/19 (8)	10/6 (2)	N/A	0.4518
	Indonesia	44/15 (2)	10/8 (2)	N/A	0.1227
	All	93/34 (10)	20/14 (4)	N/A	0.1029
Outcome classification: Cured /Recurrence/Failed/Died	S Africa	76/0/0/0	0/4/10/4	N/A	<0.0001
	Indonesia	61/0/0/0	0/2/16/3	N/A	<0.0001
	All	137/0/0/0	0/6/26/7	N/A	<0.0001
RNASeq subset	S Africa	26	6	0	-
	Indonesia	23	8	0	-
	All	49	14	0	-
MLPA subset	S Africa	76	18	27	-
	Indonesia	58	21	0	-
	All	135	39	27	-

666 \$ Comparison of TB patients with Good or Poor TB treatment outcome, HC excluded

Table 2. Clusters of genes differentially expressed between TB patients with good or poor treatment outcomes to TB treatment in MaSigPro analysis of combined RNA-Seq data from South Africa and Indonesia

Cluster Number	Overall pattern	Number of gene transcripts	Gene Function				Top Functions from g:Profiler** with adjusted P<0.05
			Protein Coding	Processed Transcript	Pseudogene	Regulatory RNAs*	
1	↓ through treatment; Higher in Good at W2	26	20	1	0	5	GO:MF – Opsonin Binding; GO:CC – Intracellular Vesicles; Endomembrane System
2	↑ through treatment; Higher in Poor throughout	14	13	0	0	1	GO:BP – B cell receptor (BCR) signaling; GO:CC – BCR complex KEGG – BCR signaling; primary immunodeficiency; REAC – BCR signaling WP – BCR signaling CORUM – CIN85-BLNK complex
3	↑ through treatment; Higher in Good at W26	25	17	2	0	6	<i>No significant results</i>
4	↓ through treatment; Higher in Poor throughout	47	37	2	2	6	GO:CC – Arp2/3 complex; KEGG – Shigellosis; E.coli, Yersinia, Salmonella infection; Endocytosis; REAC – Ephrin signaling; Rho GTPases activate WASPs and WAVES; TF – ZNF544 CORUM – Arp2/3 complex
5	Small ↓ through treatment; Higher in Poor throughout	11	6	1	1	3	GO:MF – L-tyrosine transmembrane transporter activity; GO:BP – positive regulation of fatty acid transport.
6	No change; Higher in Poor throughout	4	0	0	3	1	<i>No significant results</i>
7	↑ to W2, then ↓; Higher in Poor at W2	4	4	0	0	0	GO:BP – mitotic cell cycle process WP – Retinoblastoma Gene in Cancer
8	↑ in Good through treatment; No change in Poor	7	3	0	2	2	GO:MF – RNA polymerase III activity
9	↓ through treatment; Much greater change in Good	10	10	0	0	0	GO:MF – immunoglobulin receptor binding GO:BP – phagocytosis, recognition; complement activation, classical pathway; immunoglobulin mediated immune response; B cell activation GO:CC – immunoglobulin complex; E/C space; plasma membrane REAC – Classical antibody-mediated complement activation; FCGR activation; phagocytosis.

*Retained introns, Antisense, LncRNA, miRNA, nonsense-mediated decay, sense overlapping, sense intronic, snoRNA,

**Redundant G:Profiler results are not shown

Table 3. dcRT-MLPA Gene signatures Good versus Poor obtained by pooling the study groups and the cohorts

Diagnosis Signature

Gene	Module
GBP1	IFN signaling genes
FCGR1A	IFN signaling genes
STAT1	IFN signaling genes
IFITM3	IFN signaling genes
BCL2	Apoptosis - Survival
CCL4	Treg associated genes
TLR9	Pattern recognition receptors
CD274	IFN signaling genes

Week two Signature

Gene	Module
GBP5	IFN signaling genes
INDO	IFN signaling genes
GBP1	IFN signaling genes
BMP6	Cell growth - proliferation
CXCL9	Chemokines
GATA3	Th2 associated genes
FCGR1A	IFN signaling genes
MMP9	Inflammation
PTPRCv1	T cell subset markers
SPP1	Inflammation
CD3E	T cell subset markers
ASAP1	Small GTPases - (Rho) GTPase activating proteins
IL5	Th2 associated genes
TNFRSF1B	Apoptosis - Survival
NLRP2	Inflammasome components
MRC1	Pattern recognition receptors
NLRP6	Inflammasome components
IL22RA1	Th17 associated genes
VEGF	Cell growth - proliferation
KIF1B	Intracellular transport
CCL19	Chemokines
CD209	Pattern recognition receptors

Month 2 Signature

Gene	Module
BLR1	G protein-coupled receptors
BMP6	Cell growth - proliferation
CCL13	Chemokines
GBP1	IFN signaling genes
GBP2	IFN signaling genes
GBP5	IFN signaling genes
IFI16	IFN signaling genes
IL9	Th9 associated genes
INDO	IFN signaling genes
MMP9	Inflammation
NOD2	Pattern recognition receptors
OAS3	IFN signaling genes
PTPRCv2	T cell subset markers
TAP1	IFN signaling genes

Genes that appeared in more than one gene signature (diagnosis, week two or month two) are shown in bold. Gene signatures were obtained by down-sampling the majority class (good treatment outcome).

Figure legends

Figure 1. MDP plots representing the change in gene expression perturbation in TB patients categorized based on treatment outcome. Full blood transcriptomes from TB patients who had a good or poor treatment outcome were determined by (A) RNA-Seq and by (B) dcRT-MLPA. The extent of overall difference in gene expression, relative to the median of expression at diagnosis in those who had a good treatment outcome, was calculated for individual patients at the timepoints shown. The bars and whiskers show the median and data within the $Q_1-1.5 \times \text{IQR}$ and $Q_3+1.5 \times \text{IQR}$ interval. Differences were significant by Mann-Whitney U-test with Benjamini-Hochberg correction for multiple testing. * $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$.

Figure 2. MaSigPro analysis of TB patients with good or poor treatment outcome, across combined South African and Indonesian cohorts. Plots show hierarchical clusters of genes in patients with a good (blue) or poor (red) treatment outcome. Bars show mean ± 1 SEM. Data were filtered to remove lowly abundant transcripts prior to analysis.

Figure 3. DEA of all TB patients from the pooled (South African and Indonesian) cohorts categorized based on treatment outcome compared to their gene expression levels at diagnosis. (A) Volcano plots representing DEGs regulated during anti-TB treatment of TB patients who had a good treatment outcome (left panel) or a poor treatment outcome (right panel). The y-axis scales of the plots are harmonized per treatment outcome. $-\log_{10}$ -transformed p-values are plotted against $\log_2$ FC. Genes with $p<0.05$ and $\log_2$ FC <-0.6 or >0.6 were labelled as DEGs. (B) Heatmaps displaying $\log_2$ FC of the DEGs and corresponding gene modules. The saturation of color represents the magnitude of differential expression. Differences were significant by means of linear mixed models. * $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$.

Figure 4. Prediction of treatment outcome in dcRT-MLPA data from peripheral blood. (A) ROC curves showing the predictive power of the gene signatures identified in the balanced pooled cohort (South Africa and Indonesia) to classify TB patients at diagnosis (left panel), two weeks (middle panel) or two months (right panel) after initiation of anti-TB treatment into patients who had a good treatment outcome and patients who had a poor treatment outcome, using the RFE-RF model and LOOCV. The dataset was balanced by down-sampling to encompass the same number of individuals with poor and good treatment outcome (diagnosis, $n=34$; week two, $n=33$; month two, $n=34$). (B) Gene expression kinetics of the single genes encompassing the diagnosis or week two gene signatures predicting treatment outcome in the pooled cohort. Box plots depict *GAPDH*-normalized, $\log_2$ -transformed median gene expression values and the IQR, while the whiskers represent the data within the $Q_1-1.5 \times \text{IQR}$ and $Q_3+1.5 \times \text{IQR}$ interval. (C). ROC curves showing the predictive power of the gene signatures identified in the balanced pooled cohort (South Africa and Indonesia) to classify TB patients from an external validation cohort (India) at diagnosis (left panel) or two months (right panel) after initiation of anti-TB treatment into patients who had a good treatment outcome and patients who had a poor treatment outcome. The dataset was balanced by down-sampling to encompass the same number of individuals with poor and good treatment outcome (diagnosis, $n=22$; month two, $n=22$). Abbreviations: AUC, area under the curve; CI, confidence interval.

Figure 1

Figure 2

a

b

Figure 3

Figure 4

Supplementary Information

Reverse-Transcriptase Multiplex Ligation-dependent Probe Amplification (dcRT-MLPA)

For each target-specific sequence, a specific RT primer was designed located immediately downstream of the left- and right-hand half-probe target sequence. 125 ng RNA was reverse transcribed to cDNA by incubation at 37°C for 15 min, using RT-primer mix and Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (Promega, Leiden, The Netherlands). Reverse transcriptase was inactivated by heating at 98°C for two minutes. The left- and right-hand half probes were hybridized to the cDNA at 60°C overnight and annealed half-probes were ligated at 54°C for 15 minutes using ligase-65 (MRC-Holland). Ligase-65 was subsequently inactivated by heating at 98°C for five minutes. Ligated probes were amplified by PCR: 33 cycles at 95°C for 30 seconds, 58°C for 30 seconds and 72°C for 60 seconds, followed by one cycle at 72°C for 20 minutes. PCR products were 1:10 diluted in Highly deionized (Hi-Di) formamide (ThermoFisher) containing 400HD Rhodamine X (ROX) fluorophore size standard (ThermoFisher). PCR products were denatured at 95°C for five minutes, stored immediately at 4°C and analyzed on an Applied Biosystems 3730 capillary sequencer in GeneScan mode (BaseClear, Leiden, The Netherlands). Trace data were analyzed using GeneMapper software 5 (Applied Biosystems, Warrington, UK). The areas of each assigned peak (arbitrary units) were exported for analysis in R (version 3.6.3). Data were corrected for batch effect and normalized to housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*). Signals below the threshold value for noise cutoff in GeneMapper (log2 transformed peak area 7.64) were assigned the threshold value for noise cutoff.

RT primers and half-probes were designed by Leiden University Medical Centre (LUMC, Leiden, The Netherlands) and comprised sequences for four housekeeping genes and

144 selected key immune-related genes to profile the following compartments of the human immune response (Supplementary Table S1): (1) Adaptive immune responses: T-cell responses; Th1 responses; Th2 responses; Th17/22 responses; Treg responses; T-cell cytotoxicity; Immune cell subset markers including B-cells and NK-cells. (2) Innate immune responses: Myeloid-associated markers and scavenger receptors; Pattern recognition receptors; Inflammasome components. (3) Inflammatory and IFN-signalling genes. (4) Other genes: Anti-microbial activity; Apoptosis/cell survival; E3 ubiquitin protein ligases; Small GTPases/(Rho)GTPase activating proteins; Additional chemokines; Cell growth/proliferation; Cell activation; Transcriptional regulators/activators; Intracellular transport; Mitochondrial Stress/Proteasome; Inflammation.

Linear Mixed Models for identification of DEGs

Longitudinal DEGs were identified by means of linear mixed models using the lmer function of the lme4 package in R.⁴⁷ To increase statistical power, datasets of all TB patients included in the South African and Indonesian cohorts were pooled independent of diabetes/glycaemia status and split based on treatment outcome. Models were fitted on *GAPDH*-normalized log₂-transformed targeted gene expression data. Outcome-time interactions were included as fixed effects and the patients ID-time interactions were included as random effects.

Identification of gene signatures for treatment outcome

For modelling analyses, RNA-Seq data were randomly split into training and test sets (60/40) using the R package *caret*.⁵¹ Feature selection was performed for each timepoint using RFE⁴⁸ with repeated cross validation as the re-sampling method (n=10). A weighted model was fitted using glmnet method, using weights 1/frequency * 0.5 and repeated cross validation for re-sampling (n=10). Each model was used to make predictions on the corresponding test set.

To identify signatures associated with treatment outcome in dcRT-MLPA data, TB patients of South Africa and Indonesia were pooled independent of diabetes/glycaemia status. To balance the dataset, we applied two random sampling approaches using R: (1) a down-sampling approach, reducing the number of patients in the majority class (i.e. good treatment outcome) and (2) an up-sampling approach by generating synthetic data from existing data using the SMOTE⁴⁹ function from the *DMwR* package in R, resulting in equal numbers of patients in both classes. Then, RFE⁴⁸, available in the *caret* R package⁵¹, was applied with K-fold validation (K=10) to the entire data set search for the optimal combination and number of top-ranking genes able to separate TB patients with a good and poor treatment outcome. RFE is a powerful approach for variable selection in high-dimensional data by selecting features that fit a model and removing the weakest feature (or features) until the specified number of features is reached. Once the best predictors of treatment outcome were identified, the expression values of these genes were extracted from the dataset. We subsequently applied RF⁵⁰ as machine learning algorithm on the dataset and evaluated the performance by LOOCV, both available on the *caret* R package.⁵¹

Supplementary Figure S1. MDP plot representing the change in gene expression perturbation in TB patients from South Africa categorized based on treatment outcome. Blood transcriptomes from TB patients who had a good or poor treatment outcome were determined by dcRT-MLPA. The extent of overall difference in gene expression, relative to the median of expression in healthy controls, was calculated for individual patients at the timepoints shown. The bars and whiskers show the median and data within the Q1-1.5 x inter quartile range (IQR) and Q3+1.5 x IQR interval. Differences were significant by Mann-Whitney U-test with Benjamini-Hochberg correction for multiple testing. * $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$.

a

b

Supplementary Figure S2. Differential change in gene expression in TB patients through treatment in those who had a good or poor treatment outcome. MaSigPro analysis was conducted on the blood RNA-Seq data from TB patients from South Africa (a) or Indonesia (b), to identify genes which were significantly differentially expressed between those patients with a good or poor outcome. Plots show hierarchical clusters of genes, and bars show mean $\pm$ 1 SEM. Data were filtered to remove lowly abundant transcripts prior to analysis.

Supplementary Figure S3. Cell population estimates in good and poor treatment outcomes in South Africa and Indonesia. Estimates of relative differences in cell proportions were calculated from RNA-seq data using R package CellCODE. IRIS and DMAP data sets used as reference. Bars and whiskers show median and 1.5 x IQR.

Supplementary Figure S4. Differential expression analysis in patients from South Africa and Indonesia who had a poor treatment outcome versus patients who had a good treatment outcome at the indicated timepoints. Non-parametric Mann-Whitney U-test with Benjamini-Hochberg correction for multiple testing was applied to test for statistical differences between the groups.

Supplementary Figure S5. Scatter plots representing Pearson correlations between the longitudinal DEGs identified by dcRT-MLPA versus the same genes identified by RNA-Seq. Values are plotted as log₂ FC (month six-diagnosis). Black line corresponds to line of best fit and shaded bands indicate confidence intervals.

Supplementary Figure S6. Scatter plot representing Pearson correlations between the longitudinal DEGs in TB patients who had a poor treatment outcome versus the longitudinal DEGs in TB patients who had a good treatment outcome. Values are plotted as log2 FC (month 6-diagnosis). Black line corresponds to line of best fit and shaded bands indicate confidence intervals. Red shaded areas indicate genes that were identified as DEGs only in patients who had a good treatment outcome and blue shaded areas indicate genes that were identified as DEGs only in patients who had a poor treatment outcome.

a

b

Supplementary Figure S7. Differential expression analysis of all TB patients from the South African and Indonesian cohorts categorized based on treatment outcome compared to their gene expression levels at diagnosis. (a) Volcano plots representing DEGs regulated during anti-TB treatment of TB patients from the South African cohort who had a good treatment outcome (left panel) or a poor treatment outcome (right panel). (b) Volcano plots representing DEGs regulated during anti-TB treatment of TB patients from the Indonesian cohort who had a good treatment outcome (left panel) or a poor treatment outcome (right panel). (a,b) The y-axis scales of the plots are harmonized per treatment outcome. -log10-transformed p-values are plotted against log2 FC. Genes with $p < 0.05$ and $\log_2 \text{FC} < -0.6$ or > 0.6 were labelled as DEGs.

Supplementary Figure S8. Prediction of treatment outcome in RNA-Seq data from peripheral blood. ROC curves showing the predictive power of (a) the gene signatures identified in the pooled cohort (South Africa and Indonesia) or (b) the Sweeney gene signature to classify TB patients at the indicated timepoints after initiation of anti-TB treatment into patients who had a good treatment outcome and patients who had a poor treatment outcome. Data were split into training and test sets (60/40). For each time point a gene signature was generated by RFE and a weighted model fitted using glmnet method. Weights of $1/\text{frequency} * 0.5$ were used. Abbreviations: AUC, area under the curve; CI, confidence interval.

Supplementary Figure S9. Identification of a delta (week two minus diagnosis) signature predicting the outcome of anti-TB treatment. ROC curve showing the predictive power of the gene signature identified in the balanced pooled cohort to classify TB patients into patients who had a good treatment outcome and patients who had a poor treatment outcome, using the RFE - RF model and LOOCV. The dataset was balanced by down-sampling to encompass the same number of individuals with poor and good treatment outcome. Abbreviations: AUC, area under the curve; CI, confidence interval.

a Venn diagram - within cohort

b Venn diagram - between cohorts

c Venn diagram - sampling methods at diagnosis

Supplementary Figure S10. Venn diagrams showing the number of genes encompassing treatment outcome signatures as identified by RFE-RF models. (a) Venn diagram displaying the number of unique and overlapping genes comparing diagnosis (blue), week two (orange) and month two (green) gene signatures obtained by random-downsampling. (b) Venn diagram displaying the number of unique and overlapping genes comparing the gene signatures in the current study (diagnosis, week two and month two; orange) obtained by random-downsampling with the gene signatures published by Sivakumaran et al. (blue). (c) Venn diagram displaying the number of unique and overlapping genes comparing the diagnosis gene signature obtained by random-downsampling (blue) with the diagnosis gene signature obtained by applying SMOTE sampling (orange) to balance the classes. Overlapping genes are annotated.

Supplementary Figure S11. Identification of a SMOTE diagnosis signature predicting the outcome of anti-TB treatment. ROC curves showing the predictive power of the gene signatures identified in the balanced pooled cohort (South Africa and Indonesia) and validated in the South African and Indonesian cohort or in an external Indian cohort. TB patients are classified into patients who had a good treatment outcome and patients who had a poor treatment outcome at diagnosis, using the RFE - RF model and LOOCV. The dataset was balanced by SMOTE to encompass the same number of individuals with poor and good treatment outcome. Abbreviations: AUC, area under the curve; CI, confidence interval.

Supplementary Table S1. List of target genes for dcRT-MLPA.

Module	Gene
Immune cell subset markers - B cells	CD19
NK cells	NCAM1
T cell subset markers	CD3E CD4 CD8A CCR7 PTPRCv1 PTPRCv2 AIRE IL7R
Th1 associated / IFN signaling genes	CXCL10
Th1 associated genes	IFNG IL1B IL2 IL15 TBX21 TNF
Th2 associated genes	GATA3 IL4 IL482 IL5 IL6 IL10 IL13
Th9 associated genes	IL9
Th17 associated genes	IL17A RORC IL22RA1
Treg associated genes	CCL4 CTLA4 FOXP3 IL2RA LAG3 TGFB1 TNFRSF18
Cytotoxicity markers	GNLY GZMA GZMB PRF1
Apoptosis / Survival	CASP8 BCL2 FASLG FLCN1 TNFRSF1A TNFRSF1B
Myeloid-associated genes	CD14 CD163 CCL2 CCL3

	CCL5 CCL22 CXCL13 IL12A IL12B IL23A FPR1
Chemokines	CCL11 CCL13 CCL19 CXCL9 CX3CL1
Pattern recognition receptors	CD209 CLEC7A MRC1 MRC2 NOD1 NOD2 TLR1 TLR2 TLR3 TLR4 TLR5 TLR6 TLR7 TLR8 TLR9 TLR10
Inflammasome components	NLRC4 NLRP1 NLRP2 NLRP3 NLRP4 NLRP6 NLRP7 NLRP10 NLRP11 NLRP12 NLRP13
IFN signaling genes	CD274 FCGR1A GBP1 GBP2 GBP5 IFI6 IFI16 IFI35

	IFI44 IFI44L IFIH1 IFIT2 IFIT3 IFIT5 IFITM1/3 INDO IRF7 OAS1 OAS2 OAS3 SOCS1 STAT1 STAT2 TAP1 TAP2
Inflammation	DSE MMP9 SPP1 TIMP2 TNIP1
Cell growth / Proliferation	BMP6 TGFB2 AREG EGF VEGF
Cell activation	HCK LYN SLAMF7
Small GTPases / (Rho) GTPase activating proteins	ASAP1 RAB13 RAB24 RAB33A TAGAP TBC1D7
Anti-microbial activity	BPI LTF
E3 ubiquitin protein ligases	NEDD4L
Scavenger receptors	MARCO
G protein-coupled receptors	BLR1
Transcriptional regulators/activators	CAMTA1 TWIST1 ZNF331 ZNF532
Intracellular transport	SEC14L1 KIF1B
Mitochondrial Stress / Proteasome	HPRT
Housekeeping	ABR B2M GAPDH GUSB

Supplementary Table S7. Gene signatures for each timepoint - RNA-Seq

Diagnosis	Week 2	Month 2	Month 6
MADCAM1	FGFR3	CD79B	DNMT3B
MTFR2	ICAM3	PIK3CB	HAUS4
TM4SF1	SLC7A4	MEF2BNB-MEF2B	SLC22A18
CLCN1	PACSN2	TCL1A	RTN4
WASF4P	HPN	TANGO6	CCRL2
ANKDD1B	ERGIC1	PTGES3	SERPINE2
HIST1H2BO	IL1R2	DOCK7	LYSMD2
TCTEX1D2	SSPN	ZNHIT6	WASH2P
RPSAP54	DOK4	KIF14	IL17RC
WASH4P	PRKCG	PARD6B	ARFIP1
AC026185.1	TCN1	E2F5	CCDC68
RPS2P44	GCM1	AK7	PPP1R14A
RP11-466P24.6	GAS2L3	MPZL2	RIMBP3
RP11-1105G2.4	SYT2	AKR1E2	Y_RNA
RP11-229P13.25	NR1I2	OXSRI	MIR140
MIR3136	TENM4	CNIH2	LEPROT
CTB-50L17.9	SLC45A3	ACBD7	RPL18P10
RP11-272L13.4	WNK2	TNF	AC099552.2
RP11-92K15.3	DPCD	PTGES3L	RP11-544A12.5
RP11-305L7.7	CXCL11	SPIB	FLT1P1
	B3GALNT1	USP32P1	RP11-295K2.3
	SLC22A1	IGHD	RP11-56M3.1
	HIST1H2AJ	GOLGA2P7	AC132186.1
	SNRNP35	AC096579.7	C1orf213
	CLCN1	RP11-458F8.1	UGDH-AS1
	CTD-3088G3.8	AC002543.2	RP11-175P13.3
	SULF2	IGKV1D-16	RP11-638I2.10
	CLEC4C	LINC00617	RP11-705O1.8
	RNU6-1079P	RP11-407G23.4	SEN3-EIF4A1
	AGAP7	RP11-588K22.2	RP11-401F2.3
	STARD7-AS1	RP11-325K4.2	RP11-1109F11.3
	YBX1P1	AL133153.1	U91328.22
	PRRT4	RP11-479F13.1	
	LINC01001		
	BCAS2P2		
	RP11-459O1.2		
	AL627309.1		
	IFNG-AS1		
	CTD-3051D23.4		
	RP4-647C14.3		
	CTD-2006K23.1		
	RP11-457M11.5		
	BX649553.4		
	CTB-39G8.3		
	MUC8		
	AC092299.8		

Supplementary Table S8. Delta signature Good vs Poor obtained by pooling the study groups and the cohorts.

Delta (Week two - Diagnosis) Signature

Gene	Module
GNLY	Cytotoxicity markers
MRC1	Pattern recognition receptors
GBP5	IFN signaling genes
NLRP1	Inflammasome components
FLCN1	Apoptosis - Survival
ZNF532	Transcriptional regulators - activators
IFIT2	IFN signaling genes

Genes that appeared also in the diagnosis or week two gene signatures are shown in bold. Gene signatures were obtained by downsampling the majority class (Good treatment outcome).

Supplementary Table S9. SMOTE signature Good vs Poor obtained by pooling the study groups and the cohorts.

Diagnosis Signature

Gene	Module
AREG	Cell growth - proliferation
BCL2	Apoptosis - Survival
CASP8	Apoptosis - Survival
CCL13	Chemokines
CD209	Pattern recognition receptors
CLEC7A	Pattern recognition receptors
CTLA4	Treg associated genes
CX3CL1	Chemokines
FCGR1A	IFN signaling genes
GBP1	IFN signaling genes
IL12B	Myeloid associated genes
LTF	Anti-microbial activity
NLRP3	Inflammasome components
STAT1	IFN signaling genes
TIMP2	Inflammation
TLR8	Pattern recognition receptors
TLR9	Pattern recognition receptors
TNFRSF1A	Apoptosis - Survival
ZNF331	Transcriptional regulators - activators

Gene signature obtained by applying SMOTE sampling technique. Genes that are also identified in the Diagnosis signature obtained by downsampling are shown in bold.